Effect of Ketoconazole on Biliary Excretion of AZD0837
- Registration Number
- NCT00812344
- Lead Sponsor
- AstraZeneca
- Brief Summary
This is an explorative study and the scientific question to be investigated is if the biliary excretion of AZD0837 and its metabolites AR-H069927XX and AR-H067637XX are affected by co-administration with ketoconazole
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
- body mass index (BMI) between 19 to 30 kg/m2 and body weight between 50 to 100 kg inclusive
Exclusion Criteria
- Significant illness, trauma or surgical procedures.
- Clinically significant laboratory abnormalities.
- Clinically significant medical history
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 AZD0837 - 2 AZD0837 AZD0837 + Ketoconazole 2 ketoconazole AZD0837 + Ketoconazole
- Primary Outcome Measures
Name Time Method Amount of AZD0837, AR-H069927XX, and AR-H067637XX in bile and biliary clearance of AZD0837, AR-H069927XX, and AR-H067637XX. Frequent sampling through a Loc-I-Gut catheter for up to 3 hours post dose.
- Secondary Outcome Measures
Name Time Method PK variables of AZD0837, AR-H069927XX, and AR-H067637XX. Frequent sampling during 24 hours. Adverse events, physical examination, safety laboratory variables, blood pressure, pulse and electrocardiography. Some of the safety variables will be followed at each visit, some less frequent. Pharmacogenetics One sampling during the study.
Trial Locations
- Locations (1)
Research Site
πΈπͺUppsala, Sweden